Independent Study Results Presented At American Society For Dermatologic Surgery Annual Meeting Show That DUSA Pharmaceuticals's (DUSA) Levulan(R) Kerastick(R) Plus Intense Pulsed Light "IPL" Improves Photodamaged Skin More Than IPL Alone
10/19/2005 5:11:45 PM
DUSA Pharmaceuticals, Inc. (NASDAQ:DUSA) is pleased to report that at the annual meeting of the American Society for Dermatologic Surgery in San Diego, held September 30th to October 3rd, 2004, an independent investigator group presented the results of the first prospective, randomized, controlled, split face clinical study using the Levulan(R) (aminolevulinic acid HCl) Kerastick(R) together with intense pulsed light (IPL) for the treatment of photoaging. DUSA provided Levulan and financial support to the investigator group.
comments powered by